Benzinga | May 7, 2021 07:41AM EDT

GSK and Vir Biotechnology Earlier Announced The Start Of The EMA Rolling Review of VIR-7831 For The Early Treatment Of COVID-19

-- Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 --

-- Review will support a formal Marketing Authorization Application --

-- GSK and Vir continue discussions with global regulators to make sotrovimab

available to patients with COVID-19 --